Farallon Capital Management Adds $69M in Dianthus Therapeutics, Inc. ($DNTH)
Key Points
- Wall Street's consensus rating on $DNTH is Strong Buy and an average price target of $127.67.
- $DNTH last traded around $82.07.
Farallon Capital Management acquired a new position in Dianthus Therapeutics, Inc. ($DNTH), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 836,000 shares of Dianthus Therapeutics, Inc.. Farallon Capital Management's holdings in Dianthus Therapeutics, Inc. were worth $68.61 million as of its most recent filing.
Dianthus Therapeutics, Inc. ($DNTH) Stock
Dianthus Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.